Cargando…
Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
OBJECTIVE: Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP. Recently, it was shown that raltegravir could inhibit cell‐free and cell‐to...
Autores principales: | Enose‐Akahata, Yoshimi, Billioux, Bridgette Jeanne, Azodi, Shila, Dwyer, Jennifer, Vellucci, Ashley, Ngouth, Nyater, Nozuma, Satoshi, Massoud, Raya, Cortese, Irene, Ohayon, Joan, Jacobson, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528465/ https://www.ncbi.nlm.nih.gov/pubmed/34562313 http://dx.doi.org/10.1002/acn3.51437 |
Ejemplares similares
-
Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2019) -
Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2018) -
HTLV-1 epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional proliferative suppression of Tregs
por: Anderson, Monique R, et al.
Publicado: (2014) -
Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017) -
Correlation of increased CXCL13 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2014)